Are mammotropic hormones mainly permissive for the development of breast cancer?

International Journal of Cancer

Volumn 118, Issue 11, 2006, Pages 2863-2865

  Trichopoulos, Dimitrios ^a,b   Bamia, Christina ^b   Lagiou, Pagona ^a,b   Trichopoulou, Antonia ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Breast cancer; Cohort; Estrogens; European Prospective Investigation into Cancer and Nutrition (EPIC); Hormones; Mammotropic hormones; Permissive

Indexed keywords

ANDROSTENEDIONE; ESTROGEN; ESTRONE; HORMONE; MAMMOTROPIC HORMONE; PRASTERONE SULFATE; SOMATOMEDIN C; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; AGED; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MENOPAUSE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TESTOSTERONE BLOOD LEVEL;

ADULT; AGE FACTORS; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GONADAL STEROID HORMONES; HUMANS; INCIDENCE; INSULIN-LIKE GROWTH FACTOR I; MENOPAUSE; MIDDLE AGED; ODDS RATIO;

EID: 33646380857     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21718     Document Type: Article

References (21)

1. Key T, Appleby P, Barnes I, Reeves G; Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
2. Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C, Rosner B, Speizer FE. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999;91:629-34.
3. Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS, Wang DY. A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. Br J Cancer 1997;75:1075-9.
4. Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, Secreto G, Amiano P. Bingham S, Boeing H, Bueno de Mesquita HB, Chang-Claude J, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2005;97:755-65.
5. MacMahon B, Cole P, Brown JB, Paffenbarger R, Trichopoulos D, Yen S. Urine estrogens, frequency of ovulation, and breast cancer risk: case-control study in premenopausal women. J Natl Cancer Inst 1983;70:247-50.
6. Sturgeon SR, Potischman N, Malone KE, Dorgan JF, Daling J; Schairer C, Brinton LA. Serum levels of sex hormones and breast cancer risk in premenopausal women: a case-control study (USA). Cancer Causes Control 2004;15:45-53.
7. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346-53.
8. Lee SA, Ross RK, Pike MC. An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 2005;92:2049-58.
9. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, Noguchi S. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 2003;9:5699-704.
10. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, Trichopoulos D. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004;89:1102-7.
11. Yu H, Shu XO, Li BD, Dai Q, Gao YT, Jin F, Zheng W. Joint effect of insulin-like growth factors and sex steroids on breast cancer risk. Cancer Epidemiol Biomarkers Prev 2003;12:1067-73.
12. Trichopoulos D, Lagiou P, Adami HO. Towards an integrated model for breast cancer etiology: the crucial role of the number of mammary tissue-specific stem cells. Breast Cancer Res 2005;7:13-17.
13. Siemiatycki J, Wacholder S, Dewar R, Cardis E, Greenwood C, Richardson L. Degree of confounding bias related to smoking, ethnic group, and socioeconomic status in estimates of the associations between occupation and cancer. J Occup Med 1988;30:617-25.
14. MacMahon B, Trichopoulos D. Epidemiology: principles and methods, 2nd ed. Boston: Little Brown, 1996.
15. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, Charrondiere UR, Hemon B, Casagrande C, Vignat J, Overvad K, Tjonneland A, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002;5:1113-24.
16. Bezemer ID, Rinaldi S, Dossus L, Gils CH, Peeters PH, Noord PA, Bueno-de-Mesquita HB, Johnsen SP, Overvad K, Olsen A, Tjonneland A, Boeing H, et al. C-peptide, IGF-I, sex-steroid hormones and adiposity: a cross-sectional study in healthy women within the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control 2005;16:561-72.
17. Rolf C, Nieschlag E. Potential adverse effects of long-term testosterone therapy. Baillieres Clin Endocrinol Metab 1998;12:521-34.
18. Signorello LB, Adami HO. Prostate cancer. In: Adami HO, Hunter D, Trichopoulos D, eds. Textbook of cancer epidemiology. New York: Oxford University Press, 2002.400-28.
19. Gronberg H. Prostate cancer epidemiology. Lancet 2003;361:859-64.
20. Huber M, Poulin R. Permissive role of polyamines in the cooperative action of estrogens and insulin or insulin-like growth factor I on human breast cancer cell growth. J Clin Endocrinol Metab 1996;81:113-23.
21. Balasenthil S, Vadlamudi RK. Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein. J Biol Chem 2003;278:22119-27.